Product Description
Mechanisms of Action: Calcium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: LG
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Hypertension, Renal|Kidney Failure, Chronic|Stroke|Hypertension|Proteinuria|Angina Pectoris|Other
Phase 3: Hypertension|Other
Phase 2: Hypertension
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BAR-MEDS Lercanidipine | N/A |
Recruiting |
Obesity, Morbid |
2026-10-01 |
|
| ChiCTR2200059596 | N/A |
Not yet recruiting |
Glioblastoma |
2024-12-31 |
|
| CTR20201599 | N/A |
Completed |
Hypertension |
2020-09-19 |
|
| PROERCAN01 | P4 |
Unknown status |
Proteinuria|Kidney Failure, Chronic |
2019-12-01 |